Advertisement

Ischemix LLC, a biotechnology firm in Maynard, has returned positive data on its drug candidate to prevent peri-operative cardiac ischemia-reperfusion injury, a temporary decrease in sufficient blood flow, in patients following percutaneous coronary intervention (PCI) procedures that are meant to treat those symptoms.

Based on the data from the Phase 2a clinical trial, Ischemix’s treatment, called CMX-2043, was found to be safe at all doses and also landed certain endpoints in measuring cardiac health.

SOURCE

Advertisement
Advertisement